vai alle Pubblicazioni
Publications prior to 2004
Pubblicazioni del Prof. Giovanni Martinelli nel 2010 su
riviste.
1. Follo et al. Synergistic induction of PI-PLCβ1 signaling by
azacitidine and valproic acid in high-risk myelodysplastic
syndromes. Leukemia : official journal of the Leukemia Society of
America, Leukemia Research Fund, UK (2010).
2. Kantarjian et al. Nilotinib is effective in patients with
chronic myeloid leukemia in chronic phase following imatinib
resistance or intolerance: 24-month follow-up results. Blood
(2010).
3. Della Peruta et al. Protein tyrosine phosphatase receptor type
{gamma} is a functional tumor suppressor gene specifically
downregulated in chronic myeloid leukemia. Cancer Research (2010)
vol. 70 (21) pp. 8896-906
4. Lo-Coco et al. Front-line treatment of acute promyelocytic
leukemia with AIDA induction followed by risk-adapted consolidation
for adults younger than 61 years: results of the AIDA-2000 trial of
the GIMEMA Group. Blood (2010) vol. 116 (17) pp. 3171-9.
5. Soverini et al. IDH2 somatic mutations in chronic myeloid
leukemia patients in blast crisis. Leukemia : official journal of
the Leukemia Society of America, Leukemia Research Fund, UK (2010).
6. Iacobucci et al. The PAX5 gene is frequently rearranged in
BCR-ABL1-positive acute lymphoblastic leukemia but is not
associated with outcome. A report on behalf of the GIMEMA Acute
Leukemia Working Party. Haematologica (2010) vol. 95 (10) pp.
1683-90
7. Baldazzi et al. B-cell acute lymphoblastic leukemia as
evolution of a 8p11 myeloproliferative syndrome with
t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leuk Res (2010) vol. 34
(10) pp. e282-5.
8. Papayannidis et al. Philadelphia positive (Ph+) acute
lymphoblastic leukemia (ALL) patient with breast infiltration. Leuk
Res (2010) vol. 34 (9) pp. e246-7.
9. Castagnetti et al. Deletions of the derivative chromosome 9
do not influence the response and the outcome of chronic myeloid
leukemia in early chronic phase treated with imatinib mesylate:
GIMEMA CML Working Party analysis. J Clin Oncol (2010) vol. 28 (16)
pp. 2748-54.
10. Mancini et al. mTOR inhibitor RAD001 (Everolimus) enhances the
effects of imatinib in chronic myeloid leukemia by raising the
nuclear expression of c-ABL protein. Leuk Res (2010) vol. 34 (5)
pp. 641-8.
11. Lilly et al. Dasatinib 140 mg once daily versus 70 mg twice
daily in patients with Ph-positive acute lymphoblastic leukemia who
failed imatinib: Results from a phase 3 study. Am J Hematol (2010)
vol. 85 (3) pp. 164-70
